checkAd
    Startseite > Aktien > Zai Lab > Nachrichten
    Zai Lab Aktie
    17,920
     
    USD
    -5,98 %
    -1,140 USD
    Letzter Kurs 25.05.24 Nasdaq
    17,910
     
    USD
    800 STK
    Geldkurs 24.05.24
    17,940
     
    USD
    400 STK
    Briefkurs 24.05.24
    ISIN: US98887Q1040 · WKN: A2DX1V · SYM: ZLAB · Kaiman-Inseln

    Neueste Nachrichten

    Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
    22.05.24 · Business Wire (engl.) · Zai Lab
    Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
    20.05.24 · Business Wire (engl.) · Zai Lab
    Zai Lab Announces Participation in May and June Investor Conferences
    16.05.24 · Business Wire (engl.) · Zai Lab
    Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
    14.05.24 · Business Wire (engl.) · Zai Lab
    Zai Lab Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
    13.05.24 · Business Wire (engl.) · Zai Lab
    Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
    08.05.24 · Business Wire (engl.) · Zai Lab
    Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
    15.04.24 · Business Wire (engl.) · Zai Lab
    Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
    11.04.24 · Business Wire (engl.) · Zai Lab
    Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
    02.04.24 · Business Wire (engl.) · Zai Lab
    Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
    01.04.24 · Business Wire (engl.) · Zai Lab
    Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
    27.03.24 · Business Wire (engl.) · Zai Lab
    Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
    14.03.24 · Business Wire (engl.) · Zai Lab